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How CD4-CD8 differentiation is maintained in mature
T cells is largely unknown. The present study has ex-
amined the role in this process of the zinc finger pro-
tein Zbtb7b, a critical factor for the commitment of
MHC II-restricted thymocytes to the CD4+ lineage.
We showed that Zbtb7b acted in peripheral CD4+
T cells to suppress CD8-lineage gene expression, in-
cluding that of CD8 and cytotoxic effector genes
perforin and Granzyme B, and was important for
the proper repression of interferon-g (IFN-g) during
effector differentiation. The inappropriate expression
of IFN-g by Zbtb7b-deficient CD4+ T cells required
the activities of Eomesodermin and Runx transcrip-
tion factors. Runx activity was needed for Granzyme
B expression, indicating that Runx proteins control
expression of the cytotoxic program. We conclude
that a key function of Zbtb7b in the mature CD4+
T cell compartment is to repress CD8-lineage gene
expression.
INTRODUCTION
T lymphocytes (T cells) are critical for adaptive immune re-
sponses and are distributed into multiple lineages, the two pre-
dominant ones being defined by their reactivity against peptide
antigens bound to classical MHC molecules and by their mutu-
ally exclusive expression of CD4 or CD8 surface glycoproteins
(Janeway and Bottomly, 1994). CD4+ T cells typically recognize
MHC-II peptide complexes and upon effector differentiation
control the function of other immunocompetent cells, either pos-
itively or negatively. In contrast, CD8+ T cells generally recognize
MHC-I peptide complexes and differentiate into cytotoxic effec-
tors able to lyze virtually any nucleated cell given the broad pat-
tern of MHC-I expression. Once established in the thymus
(Singer and Bosselut, 2004), CD4-CD8 lineage differentiation is
stably maintained in peripheral T cells and is inherited through
cell division after activation and during effector differentiation.
Several transcription factors orchestrate the differentiation of
CD4+ and CD8+ cells from bipotent precursors that express
both CD4 and CD8 (double-positive [DP] thymocytes). Two876 Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc.members of the Runx family, Runx1 and Runx3, contribute to
CD8+ cell differentiation and notably to the termination of CD4
expression (Taniuchi et al., 2002a; Woolf et al., 2003), whereas
the HMG protein Tox and the zinc finger transcription factors
Gata3 and Zbtb7b (also known as Thpok, cKrox) promote the
generation of CD4+ T cells (Aliahmad and Kaye, 2008; Hernan-
dez-Hoyos et al., 2003; Pai et al., 2003; Zhu et al., 2004; He
et al., 2005; Sun et al., 2005; Wang et al., 2008).
Little is known about how CD4+-CD8+ differentiation is main-
tained in peripheral T cells. Some of the factors that promote
lineage differentiation in the thymus carry distinct functions in
post-thymic T cells. In the mature CD4+ compartment, Runx3
contributes to interferon-g (IFN-g) production and interleukin-4
(IL-4) repression during type 1 effector differentiation (Djuretic
et al., 2007; Naoe et al., 2007), whereas Runx1 promotes cell sur-
vival (Egawa et al., 2007). Gata3 promotes type 2 effector differ-
entiation and does not appear required to maintain the CD4+ lin-
eage (Zheng and Flavell, 1997; Pai et al., 2004; Zhu et al., 2004).
In differentiating thymocytes, Zbtb7b both promotes CD4-
helper and represses CD8-cytotoxic T cell differentiation (He
et al., 2005; Sun et al., 2005). Thus, because Zbtb7b expression
is CD4-lineage specific in peripheral T cells, it was possible that it
promoted the maintenance of CD4-helper gene expression or
the repression of CD8-cytotoxic gene expression, or both, in
CD4+ cells. In the present study, we tested these hypotheses
by using hypomorphic and conditional Zbtb7b alleles. We dem-
onstrated that a key function of Zbtb7b in CD4+ T cells is to pre-
vent expression of CD8 and cytotoxic genes.
RESULTS
Expression of Zbtb7b in Mature CD4+ T Cells
Weand others previously reported that Zbtb7bwas expressed in
CD4+ but not CD8+ peripheral T cells (He et al., 2005; Sun et al.,
2005; Setoguchi et al., 2008). Wemore extensively examined the
pattern of Zbtb7b expression in peripheral T cells by using a BAC
reporter transgene in which Zbtb7b cis-regulatory elements con-
trol the expression of a GFP cDNA inserted in the first Zbtb7b
coding exon (Figure 1A; Wang et al., 2008). This BAC drives un-
imodal GFP expression in spleen and lymph node (LN) CD4+ but
not CD8+ T cells, in amounts similar to those observed in mature
CD4 SP thymocytes (Figure 1B). GFP expression was similar in
naive (CD44lo) and effector or memory-type cells (CD44hi), and
in CD4+CD25+ regulatory T (Treg) cells (Figure 1C). GFP
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Zbtb7b Function in CD4 T CellsFigure 1. Expression of Zbtb7b Is CD4+ Specific
(A) The transcriptional activity of Zbtb7b cis-regulatory elements was assessed inmice carrying a BAC reporter transgene in which the first coding exon of Zbtb7b
was replaced by an eGFP cDNA (white box), so that GFP fluorescence is a readout of Zbtb7b expression. Thick boxes depict coding sequenceswithin the second
and third Zbtb7b exons.
(B) Overlaid histograms show GFP fluorescence (plain lines) in CD4+ and CD8+ LN T cells and in TCR-bhi CD4 and CD8 SP thymocytes that had downregulated
CD24 (heat stable antigen), an event characteristic of the most mature SP thymocyte subset.
(C) Two parameter contour plots show CD44 or CD25 versus GFP expression on gated CD4+CD8–peripheral T cells from Zbtb7b+/+ mice carrying the GFP BAC
reporter. Numbers indicate the percentage of cells in each quadrant.
(D) Overlaid histograms showGFP fluorescence (plain lines) in CD4+ T cells differentiating in vitro under Th1, Th2, or ThN cell-culture conditions (see Experimental
Procedures), 1 to 4 days after activation (set as day 0). Dotted histograms show GFP fluorescence of fresh CD4+ T cells analyzed in parallel. Gray-shaded histo-
grams in (B) and (D) show background fluorescence on nontransgenic cells of the same subset subject to the same treatment. Data are representative of at least
two (D) or three (B, C) independent experiments.expression in CD4+ T cells persisted after T cell activation and
during in vitro effector differentiation under T helper 1 (Th1) or
Th2 cell culture conditions (Figure 1D). These experiments indi-
cate that Zbtb7b expression is maintained throughout the life
of peripheral CD4+ T cells and prompted us to evaluate the
role of Zbtb7b in CD4+ T cell function.
CD4+ T Cells with Reduced Zbtb7b Protein Expression
Germline Zbtb7b inactivation prevents CD4+ T cell development
(He et al., 2005; Wang et al., 2008) and therefore cannot be used
to study the role of this factor in post-thymic CD4+ T cells. As an
alternative strategy, we took advantage of the targeted allele
(Zbtb7bt) we generated to disrupt Zbtb7b (Wang et al., 2008).
This allele is engineered to reduce Zbtb7b protein expressionthrough the insertion, immediately upstream of the first Zbtb7b
coding exon, of a Neo cassette flanked by splice acceptor and
transcription termination signals (Figure S1 available online).
Mice carrying one or two copies of this allele (Zbtb7bt/– or
Zbtb7bt/t) were fertile and did not display any gross developmen-
tal defect. The number of peripheral CD4+ T cells was modestly
reduced in Zbtb7bt/t mice, and most of them were naive CD44lo
cells (Figures 2A and 2B; Figure S2). The number of CD8+ T cells
was slightly increased, and analyses with T cell receptor (TCR)
transgenic Zbtb7bt/t mice indicated that this resulted from the
partial CD8-redirection of MHC II-restricted thymocytes (Figures
2D and 2E). Expression of Zbtb7b protein in peripheral CD4+
T cells was lower in Zbtb7bt/t than in wild-type mice
(Figure 2C); thus, the inserted Neo cassette impaired ratherImmunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc. 877
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Zbtb7b Function in CD4 T CellsFigure 2. CD4+ Cell Development in Mice Hypomorphic for Zbtb7b
(A) Thymocytes and splenocytes from wild-type, Zbtb7bt/t, and Zbtb7bt/– mice were analyzed by 4-color flow cytometry; Zbtb7b–/– mice (Wang et al., 2008) are
shown as a control. CD4 SP thymocytes (left) are gated on CD4 versus CD8 contour plots and analyzed for expression of TCR-b and CD24; the box indicates the
mature TCRhiCD24lo subset. CD4+ and CD8+ subsets are gated on a two-color contour plot of CD4 and CD8 expression on all live or TCR+ LN cells (right). Num-
bers indicate the percentage of cells within boxes.
(B) Bar graphs display the absolute numbers of mature CD4 (left, filled bars) and CD8 SP (right, open bars) thymocytes (TCRhiCD24lo, top) and of CD4+
andCD8+ spleen T cells (bottom). Note the x axis scales. Error bars indicate SEM. Data are from 4 (t/-) or 5mice of each genotype analyzed in three ormore distinct
experiments.
(C) Expression of Zbtb7b protein was analyzed by immunoprecipitation and immunoblotting on bead-purified CD4+ T cells from either Zbtb7bt/t or Zbtb7bt/– mice
(13107/lane) or fromwild-typecontrols (0.1–13107/lane, as indicated). The leftmost lane isanantibody-only control.Data are from2or 4 (t/-)miceof eachgenotype
analyzed together in a single experiment.
(D andE)CD8-lineage redirection inmice hypomorphic forZbtb7b. Four-parameter flowcytometrywasperformedon thymocytes fromZbtb7bt/t andZbtb7bt/–mice
and fromwild-type andZbtb7b–/–mice as controls, all carrying theMHC II-restricted AND TCR transgene that, in I-Ab-expressingmice, promotes the generation of
CD4 SP cells expressing the transgenic Va11 TCRa chain (Kaye et al., 1989).
(D) Contour plots of CD4 andCD8 expression gated on all (left) or mature (Va11hi CD24lo, right) thymocytes show the presence of both CD4 and CD8 SP subsets in
Zbtb7bhypomorphic mice, unlike in wild-type mice that only have mature CD4-lineage AND cells.878 Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc.
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Zbtb7b Function in CD4 T Cellsthan prevented Zbtb7b protein expression, and the Zbtb7bt
allele was hypomorphic. Changes in CD4 and CD8 single-posi-
tive (SP) thymocyte subsets paralleled those seen in the periph-
ery (Figures 2A, 2B, 2D, and 2E). Zbtb7bt/t thymocytes had nor-
mal expression of CD5 and CD69 (data not shown), suggesting
that TCR signal transduction operated normally in these cells,
as in thymocytes with germline Zbtb7b inactivation (Azzam
et al., 1998; Swat et al., 1993; He et al., 2005).
Zbtb7b protein expression was further reduced in Zbtb7bt/–
mice (Figure 2C), in which T cell development and homeostasis
were more severely affected. There were few mature CD4+ cells
(Figures 2A and 2B), most of which were CD44hi (Figure S2), and
a near complete redirection of MHC II-restricted thymocytes to
the CD8+ lineage (Figures 2D and 2E). Thus, even though most
Zbtb7bt/– peripheral CD4+ cells were MHC II restricted (data
not shown), they were not representative of their wild-type coun-
terparts. Consequently, we used Zbtb7bt/t mice to explore the
function of Zbtb7b in mature CD4+ T cells.
CD8-Lineage Gene Expression in Zbtb7bt/t CD4+ T Cells
Althoughmost peripheral CD4+ cells in Zbtb7bt/t mice did not ex-
press CD8, these animals had TCRhiCD4+CD8int cells that were
not found inwild-typemice (Figure 2A, second row, right column).
To evaluate whether such CD4+CD8int cells were post-thymically
derived from CD4+CD8– cells, we adoptively transferred wild-
type and Zbtb7bt/t CD4+CD8– cells (containing less than 0.1%
contaminating CD8-expressing cells, Figure S3A) into Rag2-
deficient recipients (Shinkai et al., 1992). Although wild-type do-
nors remained CD4+CD8– after transfer, a subset of Zbtb7bt/t
cells re-expressedCD8, indicating impairedCD8gene repression
(Figure 3A). CD8 expression on transferred cells was bimodal,
suggesting loss of epigenetic CD8 repression in a subset of cells.
Of note, these CD8-expressing cells did not terminate CD4 ex-
pression. These results prompted us to evaluate how reduced
Zbtb7b expression affected CD8-lineage gene expression.
We analyzed gene expression by quantitative RT-PCR (qRT-
PCR) in purified CD4+CD8–CD44lo T cells from wild-type and
Zbtb7bt/t mice. Zbtb7bt/t CD4+ cells had modestly elevated
(2-fold) expression of the cytotoxic marker perforin and of
Eomes, a T-box transcriptional activator of the cytotoxic effector
program in the CD8+ lineage (Figure 3B; Pearce et al., 2003). A
larger increase (3- to 10-fold) was seen for the cytotoxic gene
Granzyme B (GzmB), but flow cytometry failed to detect GzmB
protein expression in both Zbtb7bt/t CD4+ and wild-type CD8+
naive cells (data not shown). We assessed expression of
Runx3, which has been reported to promote CD8 expression
(Sato et al., 2005), by conventional RT-PCR to distinguish
mRNAs initiated at the distal (dis-Runx3) and proximal pro-
moters (Bangsow et al., 2001). In resting T cells, the former tran-
scripts are both characteristic of the CD8+ lineage and consid-
ered to be the main source of Runx3 protein (Egawa et al.,
2007). Although in wild-type mice dis-Runx3 transcripts were
found in CD8+ but not CD4+ cells, they were detected in CD4+
cells from Zbtb7bt/t mice (Figure 3C). In contrast, transcripts ini-
tiated at the proximal promoter, that do not appear to be effi-ciently translated in resting T cells (Egawa et al., 2007), were
present in all three cell subsets (Figure 3C). Thus, Zbtb7b hypo-
morphic CD4+ T cells fail to normally repress CD8-lineage genes.
To determine whether reduced Zbtb7b expression would re-
sult in cytotoxic gene expression during effector differentiation,
we activated wild-type and Zbtb7bt/t CD44loCD4+ T cells with
TCR and CD28 antibodies and cultured them for 5 days in the
presence of irradiated APCs and exogenous IL-2 (nonpolarizing,
ThN conditions). In such conditions, GzmB protein, normally de-
tected in CD8+ but not CD4+ cells, was expressed in Zbtb7bt/t
CD4+ T cells (Figure 3D, right). Analyses of cytokine production
showed abnormal effector differentiation in Zbtb7bt/t cells.
Whereaswild-type CD4+ T cells were skewed toward IL-4 in con-
trast to IFN-g in CD8+ T cells (Figure S4), most Zbtb7bt/t CD4+
cells produced IFN-g, and a notable fraction of those also
made IL-4 (Figure 3E). Of note, both wild-type and Zbtb7bt/t ef-
fector cells maintained a strict CD4+CD8– pattern of coreceptor
expression after in vitro activation (Figure S5 and data not
shown). CD4+ cells from Zbtb7b+/t littermates behaved like
wild-type controls in these and subsequent analyses, indicating
that the skewing toward cytotoxic differentiation did not result
from a dominant effect of the Zbtb7bt allele.
Both Zbtb7bt/t and wild-type CD4+ cells produced IL-4 and no
IFN-g when activated in Th2 cell conditions (IL-4 and antibodies
against IL-12 and IFN-g) (Figure 3E). Nonetheless, Zbtb7bt/t Th2
effector cells had higher GzmB protein and mRNA expression
than did their wild-type counterparts (Figure 3D, left, and
Figure 3F); GzmB mRNA expression was more than 1000 times
greater in effector than in resting cells (Figure S6), presumably
accounting for the lack of detectable GzmB protein expression
in naive Zbtb7bt/t cells. Activation in Th1 cell culture conditions
(IL-12 and anti-IL-4) similarly found higher expression of GzmB
protein in Zbtb7bt/t than in wild-type CD4+ effectors
(Figure S7A). The increased expression of GzmB by Zbtb7b-
insufficient effectors, irrespective of their activation conditions,
supports the conclusion that the expression of ‘‘cytotoxic’’ genes
by Zbtb7bt/t is not simply a reflection of a Th2 to Th1 cell popula-
tionshift.Of note,perforinmRNAexpression remainedwell below
those in CD8+ effectors, suggesting that they would be insuffi-
cient to allow cytolytic killing. We conclude from these experi-
ments that Zbtb7bmolecules act to prevent the aberrant expres-
sion of cytotoxic genes both in resting and effector CD4+ cells.
The Zbtb7b Hypomorphic Allele Has Minimal Effects
on CD4-Lineage Gene Expression
We next examined CD4-lineage gene expression in Zbtb7bt/t
CD4+ cells. Although expression of CD4 in resting CD4+CD8–
splenocytes or LN cells was minimally (86% ± 4%) but repro-
ducibly lower in Zbtb7bt/t cells than in their wild-type counter-
parts, expression of CD4 on activated cells was equivalent to
wild-type (Figure S5 and data not shown). Gata3 gene expres-
sion, analyzed by qRT-PCR on naive CD44loCD4+CD8– cells,
was similar in Zbtb7bt/t and wild-type mice (Figure S8A), and
so was the activity of the cis-regulatory elements that normally
control Zbtb7b gene expression (Figure 4A).(E) Absolute numbers of mature thymocytes and splenocytes are displayed as in (B); data from Zbtb7b+/t mice were obtained similarly. Data are from 3 (+/t, t/t) or
4 mice of each genotype analyzed in two distinct experiments.Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc. 879
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Zbtb7b Function in CD4 T CellsFigure 3. Inappropriate CD8-Lineage Gene Expression in Zbtb7 Hypomorphic CD4+ Cells
(A) Bead-purified CD4+CD8– cells (23 106) from wild-type or Zbtb7bt/t mice were adoptively transferred into Rag2–/– recipients. Left: starting populations. Right:
splenocytes from recipient mice were analyzed 2 weeks later by 4-color flow cytometry for expression of CD4, CD8a, TCR-b, and CD44. Single-parameter histo-
grams identify TCR+ splenocytes, on which contour plots show expression of CD4 versus CD8a and of CD4 versus CD44. Data are representative of three sep-
arate experiments (of which one with b2 m-deficient recipients), each including five recipients for each donor genotype.
(B) Expression of T-bet, Eomes, Perforin, and GzmB mRNAs was assessed by qRT-PCR in sorted naive (CD44lo) CD4+CD8– LN T cells from wild-type and
Zbtb7bt/t mice and in CD4–CD8+ LN cells from wild-type mice. Messenger RNA expression is normalized to b-actin mRNA and expressed as a ratio over those
in wild-type CD8+ cells (set to 1, not depicted). Error bars indicate SEM of triplicate determinations within the experiment shown; data are representative of three
separate such experiments.
(C) Expression of Runx3 mRNAs initiated at the distal (dis-Runx3) and proximal (prox-Runx3) promoters was analyzed by conventional RT-PCR in sorted naive
(CD44lo) CD4+CD8– LN T cells from wild-type and Zbtb7bt/t mice and in CD4–CD8+ LN cells from wild-type mice. Wedges represent 3-fold dilutions (1.2; 0.4; and
0.12 3 104 cells, respectively). b-actin mRNA expression was assessed in parallel as a control for mRNA preparation (bottom row). Data are representative of
three separate experiments.
(D–F) Sorted CD44loCD4+CD8– LN T cells from wild-type or Zbtb7bt/t mice were activated by anti-CD3 and anti-CD28 on irradiated APCs in the presence of IL-2,
IL-4, and antibodies against IL-12 and IFN-g (Th2 cell-culture conditions) or IL-2 only (ThN cell-culture conditions), and analyzed 5 days after stimulation.
(D) Cells were stained for CD4, CD8, and intracellular GzmB; GzmB expression is shown on gated CD4+CD8– Zbtb7bt/t (plain line) or wild-type (gray-filled histo-
grams); the dashed lines show GzmB expression on wild-type CD8+ cells stimulated in parallel in the same conditions.
(E) IL-4 and IFN-g production was assessed by flow cytometry on cells restimulated with PMA and ionomycin. Cells were stained for CD4, CD8, and intracellular
IL-4 and IFN-g; contour plots are gated on CD4+CD8– cells. Numbers indicate the percent of cells within quadrants.
(F) Analyses of gene expression were conducted on Th2-differentiated effectors and displayed as in (B). Data are representative of three or more separate
experiments for each panel (D–F).To analyze how Zbtb7b affected CD4+ cell effector functions,
we assessed expression of CD40 ligand (CD154), a helper mol-
ecule upregulated in CD4+ cells upon TCR engagement or after
treatment by the surrogate drug combination of PMA and iono-
mycin (Roy et al., 1993). In wild-type mice, PMA and ionomycin-
stimulated upregulation of CD40L was considerably higher in
CD4+ than in CD8+ cells, and this response was reduced by880 Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc.half in Zbtb7bt/t CD4+ cells (Figure 4B). When activated in the
proper stimulation conditions, Zbtb7bt/t CD4+ T cells differenti-
ated not only into IFN-g- or IL-4-producers (Figure 3E;
Figure S7B), but also could express IL-17 or the transcription
factor Foxp3, that in wild-type mice promotes T-regulatory dif-
ferentiation (Figure S8B; Bettelli et al., 2006; Veldhoen et al.,
2006; Reiner, 2007; Zheng and Rudensky, 2007; Sakaguchi
Immunity
Zbtb7b Function in CD4 T CellsFigure 4. Expression of CD4-Lineage Genes in Zbtb7b Hypomorphic CD4+ T Cells
(A) Transcriptional activity of Zbtb7b cis-regulatory elements in Zbtb7b hypomorphic CD4+ cells. Expression of GFP was assessed by flow cytometry in gated
CD4+CD8– LN T cells from wild-type, Zbtb7bt/t, or Zbtb7bt/– mice carrying a BAC GFP reporter for Zbtb7b expression, in which GFP expression is driven by en-
dogenous Zbtb7b cis-regulatory elements in an unmodified context. Contour plots show expression of GFP against CD44. Numbers indicate the frequency of
cells within quadrants. Data are from a least three mice of each genotype analyzed in two or more experiments.
(B) Surface expression of CD40L (CD154) was assessed by flow cytometry on B cell-depleted LN cells stimulated 4 hr with PMA and ionomycin. Overlaid
histograms are gated on CD4+CD8– cells and show CD40L expression on treated (plain lines) or untreated (gray-shaded histograms) cells. Dashed lines in-
dicate CD40L expression on gated wild-type CD4–CD8+ cells in the same culture. Numbers indicate the mean fluorescence intensity of CD40L staining on
stimulated CD4+CD8– cells. Data are from three determinations; the mean intensity of CD40L staining in Zbtb7bt/t CD4+ cells was 47% of that in their
wild-type counterparts.
(C) LN cells from wild-type, Zbtb7bt/t, or Zbtb7b–/– mice were stained for CD4, CD8, CD25, and intracellular Foxp3. Contour plots of CD4 and CD8 expression
are shown for all cells (left) or CD25+ Foxp3+ cells (right) as gated on middle-column plots. Data are from three experiments.et al., 2008). Accordingly, Zbtb7bt/t mice had subnormal num-
bers of CD4+CD25+ T cells expressing Foxp3 (Figure 4C). Al-
though in reduced numbers, CD25+ Foxp3+ cells were present
in Zbtb7b–/– mice, demonstrating that Zbtb7b is not required
for Foxp3 expression. Remarkably, even though most Zbtb7b-
deficient MHC II-restricted T cells are CD4–CD8+ T cells (He
et al., 2005; L.W. and R.B., data not shown), Foxp3 expression
was largely restricted to the residual CD4+ population
(Figure 4C). These findings suggest that Zbtb7b deficiency had
a lesser impact on CD4+ than on CD8+ markers, although their
amplitude in Zbtb7bt/t cells was not negligible given that it may
be limited by the residual expression of Zbtb7b.
Zbtb7b Is Required in Peripheral CD4+ T Cells
to Repress CD8-Lineage Genes
The present findings suggested that Zbtb7b acted in peripheral
CD4+ T cells to repress the cytotoxic program; however, they
could not exclude that CD8-lineage gene expression by
Zbtb7bt/t CD4+ cells resulted from impaired intrathymic develop-
ment. To distinguish between these possibilities, it was neces-
sary to examine mature Zbtb7b-deficient CD4+ T cells that had
developed as Zbtb7b-sufficient thymocytes. To this end, we
generated a conditional (‘‘floxed’’) Zbtb7b allele (Zbtb7bfl,
Figure S1) in which the Zbtb7b coding sequence is flanked by
two loxP sites and can be excised by the Cre recombinase.
Zbtb7bfl/fl mice had normal numbers of CD4+ T cells (Figure S9),
indicating that the floxed allele was functional.
Deletion of the floxed allele in vitro by a Cre-expressing retrovi-
rus did not affect CD4 or CD8 surface expression, but did dere-press GzmB (data not shown). We excised the floxed sequences
in vivo by using the IFN-a-responsive Mx1 promoter to express
the Cre recombinase (Kuhn et al., 1995). Treatment of Mx-Cre
transgenic Zbtb7bfl/fl mice with poly-IC (pIC), an RNA mimic that
promotes IFN-a production, resulted in a substantial, although in-
complete, deletion of the floxed allele as assessed by PCRon ge-
nomicDNA (FiguresS10AandS10B).Despite the IFN-a secretion,
pIC-treated Zbtb7bfl/fl and Mx-Cre Zbtb7bfl/fl mice retained sub-
stantial numbers of CD44loCD4+ T cells (Figure S10C).
CD4+ cells from pIC-treated Mx-Cre Zbtb7bfl/fl mice re-
expressed CD8 after adoptive transfer intoRag2-deficient hosts,
similar to Zbtb7bt/t cells (Figure 5A; Figures S3B and S3C). Thus,
post-thymic Zbtb7b expression is required in CD4+ T cells for the
sustained repression of CD8 genes. However, these CD8 re-
expressing cells remained CD4+, suggesting that Zbtb7b is not
required to maintain CD4 expression. Note that because of the
incompleteMx-Cre-induced deletion (Figure S10B), the bimodal
expression of CD8 on transferred cells cannot be interpreted
conclusively. To assess the role of Zbtb7b in effector differentia-
tion, we stimulated CD44loCD4+CD8– cells from pIC-treated
Zbtb7bfl/fl and Mx-Cre transgenic Zbtb7bfl/fl mice. Under both
ThN and Th2 differentiation conditions, peripheral Zbtb7b exci-
sion resulted in GzmB production, even though it did not affect
CD4 or CD8 surface expression (Figure 5B; Figure S10D). Post-
thymic Zbtb7b deletion resulted in the same skewing toward
IFN-g production in ThN conditions as that observed in
Zbtb7bt/t hypomorphic cells (Figure 5C). These observations
demonstrate that Zbtb7b post-thymically represses CD8-lineage
genes in CD4+ T cells.Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc. 881
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Zbtb7b Function in CD4 T CellsFigure 5. Peripheral Deletion of Zbtb7b Reactivates CD8+ Lineage Gene Expression
(A) CD4+CD8– LN cells were bead purified from pIC-treated Zbtb7bfl/fl andMx-Cre transgenic Zbtb7bfl/fl mice, 7 days after the first pIC injection, and adoptively
transferred intoRag2–/– mice. Left: Contour plots show expression of CD4 andCD8a on ex vivo LN cells and on cells purified for injection. Right: Recipient spleens
were harvested 2 weeks after transfer and analyzed by 3-color flow cytometry for expression of CD4, CD8a, and TCR-b. Contour plots (right column) show ex-
pression of CD4 and CD8a on gated TCR+ cells (gating on left column).Data are representative of three independent experiments.
(B and C) Sorted CD44loCD4+CD8– LN T cells from pIC-treated Zbtb7bfl/fl andMx-Cre transgenic Zbtb7bfl/fl micewere activated in Th2 or ThN cell conditions as in
Figure 3 and analyzed for expression of CD4, CD8, and intracellular GzmB (B) or of CD4, CD8, and intracellular IL-4 and IFN-g after PMA-ionomycin restimulation
(C). Data are representative of three such experiments.Runx3 Mediates Cytotoxic Gene Expression
in Zbtb7b-Deficient CD4+ T Cells
Because Eomes but not Runx3 was reported to activate the cy-
totoxic program in mature CD8+ T cells (Pearce et al., 2003;
Intlekofer et al., 2005; Taniuchi et al., 2002a), we predicted that
aberrant cytotoxic gene expression by Zbtb7b-insufficient cells
was caused by Eomes and would be prevented by inhibiting
Eomes activity. To evaluate this prediction, we retrovirally trans-
duced Zbtb7bt/t cells with a dominant-negative version of T-bet
(T-bet DN) that represses Eomes and T-bet target genes (Pearce
et al., 2003). As expected, expression of this virus in ThN-acti-
vatedZbtb7bt/t CD4+ cells impaired production of IFN-g, a proto-
typical target of T-box proteins (Figure 6A; Szabo et al., 2002;
Pearce et al., 2003). However, the T-bet DN virus had little or
no effect on GzmB expression, both in ThN and Th2 conditions
(Figure 6B and data not shown). Thus, the derepression of
GzmB in Zbtb7b-deficient cells was at least in part independent
from T-box protein activity.882 Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc.Consequently, we examined whether Runx3 was involved
in cytotoxic gene expression by Zbtb7b-deficient CD4+
cells. We expressed in Zbtb7bt/t CD4+ cells a truncated ver-
sion of Runx3 that includes its Runt domain and inhibits
endogenous Runx activity by occupying Runx target sites
in association with Cbfb molecules (Hayashi et al., 2000).
Transduction of the Runt virus into Zbtb7bt/t CD4+ cells in-
hibited their production of IFN-g (Figure 6A) and reversed
their aberrant GzmB expression as efficiently as did Zbtb7b
transduction (Figure 6B). Conversely, retroviral transduction
of Runx3 in wild-type CD4+ cells promoted GzmB protein
expression (Figure 6C). Together, these observations
support the conclusion that the expression of cytotoxic
genes in Zbtb7bt/t CD4+ cells is caused in part by Runx3
derepression.
In summary, the present study demonstrates that the tran-
scription factor Zbtb7b is required in post-thymic CD4+ T cells
to repress CD8-lineage gene expression.
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Most conventional TCR-ab T cells (i.e., those restricted by clas-
sical MHC molecules) are distributed into CD4+ and CD8+ line-
ages that diverge in the thymus from DP precursors, stably
express either CD4 or CD8, and harbor distinctive functional
properties. Maintaining CD4-CD8 lineage differentiation in the
peripheral repertoire ensures the continuous matching of MHC
specificity, coreceptor expression, and effector differentiation.
How this is achieved has been largely unknown.
The present study demonstrates that Zbtb7b, a key CD4+-
committing factor in the thymus, is required in peripheral CD4+
T cells to prevent the inappropriate expression of CD8-lineage
genes, including CD8, the cytotoxic effectors perforin and
GzmB, and the transcription factors Runx3 and Eomes. These
findings agree with our previous observation that Zbtb7b re-
presses cytotoxic differentiation, including perforin and GzmB
expression, when introduced into mature CD8+ T cells (Jenkin-
son et al., 2007). Such a function of Zbtb7b in peripheral CD4+
T cells is conceptually similar to the repression of aberrant
gene expression by Pax5, a transcription factor critical to estab-
lish and maintain B cell commitment (Cobaleda et al., 2007).
Two arguments suggest that Zbtb7b acts as a repressor of
CD8 genes. First, Zbtb7b belongs to a family of proteins that
generally function as transcriptional repressors, notably by re-
cruiting protein complexes that covalently modify histones or re-
model chromatin (Bilic and Ellmeier, 2007). Second, both gain-
and loss-of-function analyses show that Zbtb7b antagonizes
CD8 expression (Jenkinson et al., 2007; this study). It is possible
that Zbtb7b binds the CD8 locus and directly represses tran-
scription, that it acts indirectly by repressing activators of CD8
expression, possibly including Runx3 (Sato et al., 2005), or that
is promotes epigenetic CD8 silencing. It is difficult at present
to distinguish between these non-mutually exclusive possibili-
ties, and the lack of ChIP-grade antibodies against Zbtb7b has
so far precluded us from investigating the first hypothesis.
However, two arguments suggest that Zbtb7b promotes epige-
netic CD8 silencing: the bimodal CD8 expression by Zbtb7b-
insufficient CD4+ cells is typical of epigenetic control, and the
CD8 derepression after Zbtb7b deletion was observed only after
cell expansion, suggesting that it required proliferation to dilute
repressive epigenetic marks.
That CD8 re-expression by Zbtb7b-deficient cells was ob-
served only in vivo also suggests a requirement for ligands ab-
sent from in vitro cultures, notably IL-7 (Park et al., 2007). How-
ever, we do not think that the absence of IL-7 accounts for the
lack of CD8 re-expression by Zbtb7b-deficient CD4+ T cells;
indeed, these cells did not express CD8 when cultured in the
presence of IL-2 or IL-4, which both promote CD8 expression
similarly to IL-7 (Park et al., 2007).
That CD8 silencing in mature CD4+ cells depends on the con-
tinuous activity of Zbtb7b raises the possibility that distinct
mechanisms maintain coreceptor silencing in CD4+ versus
CD8+ T cells. CD4 expression is controlled by an enhancer active
in both CD4+ and CD8+ lineages and a silencer that recruits Runx
proteins and so far unknown additional CD4 repressors to termi-
nate CD4 expression in CD8-differentiating thymocytes (Sawada
et al., 1994; Siu et al., 1994; Taniuchi et al., 2002a, 2002b). How-
ever, whereas the silencer is required to establish silencing, it isnot needed to maintain it in CD8+ cells (Zou et al., 2001), strongly
suggesting that the repressors that bind the silencer in thymo-
cytes no longer contribute to silencing in post-thymic CD8+ cells.
In contrast, there is no known silencer element in the CD8 locus
and Zbtb7b is required both to establish and maintain CD8
silencing in the CD4+ lineage.
Unlike this effect on CD8 expression, peripheral inactivation
did not reveal a Zbtb7b requirement for sustained CD4 expres-
sion. It is possible that this is due to technical limitations of our
assays (including their relatively short timeline) or to the fact
they were mainly conducted on proliferating cells in which CD4
gene regulationmay be distinct from that in resting cells. Alterna-
tively, it is possible that Zbtb7b is not required to maintain post-
thymic CD4 expression, either because epigenetic mechanisms
‘‘lock’’ the CD4 locus in an active configuration in peripheral
CD4+ cells or because putative repressors that contribute to
CD4 silencing in CD8 SP thymocytes (Taniuchi et al., 2002b)
are no longer expressed in post-thymic T cells. Previous studies
suggest that the control of CD4 expression, and notably its re-
pression by Runx3, follows distinct rules in mature versus imma-
ture T cells (Telfer et al., 2004; Djuretic et al., 2007; Naoe et al.,
2007), and additional analyses will clarify the role of Zbtb7b in
post-thymic CD4 expression.
Similar to CD8 genes, it is possible that Zbtb7b directly re-
presses cytotoxic genes by binding to their cis-regulatory ele-
ments (Glimcher et al., 2004; Pipkin et al., 2007); the absence
of ChIP-grade antibodies against Zbtb7b currently preclude
a detailed investigation of this hypothesis. However, we docu-
ment that Zbtb7b acts at least in part by preventing or limiting
the expression of trans-activators of cytotoxic gene expression.
In CD4+ T cells, IFN-g, GzmB, and perforin are responsive to
Eomes, a trans-activator normally expressed during cytotoxic
differentiation (Pearce et al., 2003). Thus, limiting or delaying
Eomes expression during the effector differentiation of CD4+
cells appears as a key function of Zbtb7b in restraining the pro-
duction of components of the cytotoxic program that remain
‘‘accessible’’ in CD4+ cells, including IFN-g and GzmB.
Previous studies (Wargnier et al., 1995; Babichuk et al., 1996)
pointed to a potential role of Runx proteins in GzmB expression.
Our findings, using both loss- and gain-of-function approaches,
document that this is the case. Although Runx3, the predominant
Runx factor in CD8+ cells, is not required for perforin expression
or cytotoxic function (Taniuchi et al., 2002a), there is substantial
redundancy between Runx factors during CD8+ cell generation
(Woolf et al., 2003; Egawa et al., 2007; Setoguchi et al., 2008),
and it is possible that such redundancy has so far masked the
role of Runx activity in cytotoxic effector differentiation.
Runx molecules, presumably Runx3, repress Zbtb7b expres-
sion during CD8-lineage differentiation in the thymus, by binding
to a cis-regulatory element (‘‘silencer’’) upstream of the Zbtb7b
promoter (Setoguchi et al., 2008). Our finding that Zbtb7b-hypo-
morphic cells inappropriately express Runx3 raises the possibil-
ity that, conversely, Zbtb7b directly represses Runx3. Future
studieswill determine whether that is the case, in developing thy-
mocytes and mature T cells. It is possible that a two-way cross-
repression mechanism operates in thymocytes and contributes
to decide CD4-CD8 commitment by terminating expression of
one of these factors. However, it is unlikely that similar rules apply
in mature T cells, because Runx3 is upregulated in Th1 effectorsImmunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc. 883
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Zbtb7b Function in CD4 T CellsFigure 6. Expression of Cytotoxic Genes by Zbtb7b Hypomorphic CD4+ Cells Depends on Runx and T-box Protein Activities
(A and B) Bead-purified CD4+CD8– cells from Zbtb7bt/t (left) or wild-type (right) mice were activated and transduced with retroviral vectors encoding a T-bet-
engrailed chimeric protein that inhibits both T-bet and Eomes activities (T-bet DN), the Runt domain of Runx3 (Runt), or wild-type Zbtb7b (Zbtb7b), or with a con-
trol vector encoding GFP only, and analyzed after a 5-day culture in the indicated conditions for expression of CD4, CD8, and intracellular IL-4 and IFN-g (A), or of
CD4, CD8, and intracellular GzmB (B).884 Immunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc.
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Zbtb7b Function in CD4 T Cellsbut does not force the termination of Zbtb7b expression. In fact,
Runx repression of Zbtb7b expression is context dependent, as
Runx complexes (presumably involving Runx1) are bound to
the Zbtb7b ‘‘silencer’’ in CD4+ cells (Setoguchi et al., 2008).
If Zbtb7b prevents cytotoxic differentiation in part through re-
pressing cytotoxic effector regulators such as Runx3 or Eomes,
and given the overlap between Th1 and cytotoxic gene-expres-
sion programs, why is it that wild-type Th1-differentiating cells,
which express both Runx3 and Eomes, do not enter cytotoxic
differentiation (Djuretic et al., 2007; Egawa et al., 2007; Suto
et al., 2006)? We think of two non-mutually excusive possibilities
to explain this apparent paradox. First, Zbtb7b may control the
kinetics of expression of such factors, and specifically prevent
their expression in resting cells and during initial activation. Ef-
fector T cell differentiation is typically determined by the cytokine
and cell-cell interaction milieu that affect the balance of tran-
scription factor activities present during early activation (Jenkins
et al., 2001; Reiner, 2007). Thus, it is conceivable that expression
of Runx3 or Eomes in naive Zbtb7b-insufficient cells promotes
cytotoxic gene expression, whereas the transcriptional circuitry
is no longer permissive to this effect when they are expressed
at a later time point in wild-type cells. The second possibility is
that Zbtb7b acts by impairing Runx3 or T-box protein function,
possibly by directly binding to and repressing cytotoxic genes.
It is notable that Zbtb7b levels that allow CD4+ cell develop-
ment are potentially insufficient for the proper effector differenti-
ation of peripheral T cells. Future studies will determine whether
this has functional consequences in vivo during immune re-
sponses to infectious agents. However, excessive IFN-g pro-
duction by CD4+ T cells has been implicated in tissue damage
in several infectious models and in autoimmune diseases,
including type 1 diabetes (Christen and von Herrath, 2004),
and future studies will examine whether insufficient Zbtb7b ex-
pression contributes to inappropriate IFN-g production in such
circumstances.
Finally, the present study reveals a need for persistent repres-
sion of the cytotoxicCD8program inmatureCD4+ T cells. One in-
terpretation of this observation is that CD8-lineage differentiation
depends on factors that are available in peripheral lymphoid or-
gans (such as IL-7 [Singer, 2002]) and must therefore be actively
prevented in peripheral CD4+ cells. We propose that Zbtb7b is
expressed in all CD4-lineage cells to counteract such factors
and prevent the resurgence of the CD8-cytotoxic program.
EXPERIMENTAL PROCEDURES
Mice
The Zbtb7b gene-targeting strategy and the generation of the Zbtb7bt allele
were described (Wang et al., 2008) and are schematically summarized in
Figure S1. Deletion of the Frt flanked segments was obtained by crossing
mice heterozygous for the targeted allele with mice expressing Flpe underIthe control of a b-actin promoter. The genotype of recombinant animals was
verified by Southern blotting for the first two generations, and subsequently
by PCR on tail DNA. Mice carrying a GFP BAC reporter for Zbtb7b expression
were previously reported (Wang et al., 2008). Rag2–/– (Shinkai et al., 1992) and
AND TCR transgenic (Kaye et al., 1989) mice were obtained from Taconic, and
MxCre transgenic (Kuhn et al., 1995) mice were from Jax. Mice carrying the in-
dicated genotypes were generated by appropriate intercrosses or back-
crosses. Animals were genotyped by PCR on tail DNA or phenotyped by stain-
ing of peripheral blood cells andwere analyzed between 4 and 12weeks of age
except when indicated otherwise. All transgenic animals were heterozygous
for the transgenic allele. All mice were housed in specific-pathogen-free facil-
ities. Animal procedures used in the present study were approved by NCI
Animal Care and Use committees, as appropriate.
Animal Procedures
For deletion of the Zbtb7bfl allele in peripheral cells, young adult mice were in-
jected intraperitoneally with pIC (0.25 mg in 0.2 ml sterile water) three times at
2 day intervals. LN T cells were harvested for analysis 7 days after the first
injection. For adoptive transfer experiments, bead-purified CD4+CD8– thymo-
cytes (23 106) were resuspended in 0.25 ml PBS and tail vein-injected into un-
manipulated Rag2–/– recipients. Recipient splenocytes were harvested and
analyzed 2 weeks after transfer.
T Cell Activation and Effector Differentiation Cultures
Antigen-presenting cells (APCs) were obtained from C57BL/6 splenocytes by
Thy1.2 magnetic bead depletion (Dynal) and irradiated at 2500 rad. Sorted
CD44loCD4+CD8– LN or spleen T cells (0.5 3 106) were mixed with 2 3 106 ir-
radiated APCs in complete culture medium (RPMI 1640 supplemented with
10% FCS) and activated with anti-CD3 (2C11, 1 mg/ml) and anti-CD28 (3 mg/ml)
in the presence of either (1) 50 U/ml IL-2 (‘‘ThN conditions’’); (2) 50 U/ml
IL-2, 10 ng/ml IL-12, 10 mg/ml anti-IL-4 (‘‘Th1 conditions’’); (3) 50 U/ml IL-2,
100 U/ml IL-4, 10 mg/ml anti-IL-12, 10 mg/ml anti-IFN-g (‘‘Th2 conditions’’);
(4) 10 ng/ml IL-6, 5 ng/ml TGF-b1, 10 mg/ml anti-IL-4, 10 mg/ml anti-IFN-g
(‘‘Th17 conditions’’); or (5) 50 U/ml IL-2, 5 ng/ml TGF-b1, 10 mg/ml anti-IL-4,
10 mg/ml anti-IFN-g (‘‘Treg conditions’’). All cytokines were from Preprotech.
Except where indicated otherwise, cells were analyzed 5 days after activation.
For retroviral transductions, T cells activated as above were infected with su-
pernatants from Plat-E packaging cells (Morita et al., 2000) transfected with
retroviral constructs as described (Jenkinson et al., 2007). Cells were replated
in their original medium after infection.
Antibodies and Retroviral Constructs
Antibodies used for staining were from eBiosciences (anti-Foxp3) or BD-Phar-
Mingen (all others) and were used according to the manufacturer’s instruc-
tions. The anti-Zbtb7b antiserum has been described (Wang et al., 2008).
Cytokine antibodies used in T cell effector differentiation cultures were from
BD-PharMingen.
pMRX (Saitoh et al., 2002) derivatives encoding mouse Runx3 (exon 1 con-
taining isoform) or its 204 amino-terminal residues (Runt construct) were con-
structed with conventional cloning procedures (details available upon re-
quest). MSCV-derived retroviral vectors for Cre, the T-bet-Engrailed fusion
protein (T-betDN), and Gata3 were previously described (Pearce et al., 2003;
Zhu et al., 2004).
Cell Preparation, Purification, and Flow Cytometry
Cells were prepared from thymus, spleen, or lymph nodes (LN), counted, and
assessed for surface or intracellular protein expression by immunofluores-
cence and flow cytometry as described (Liu et al., 2003), with either an LSR(A) Contour plots of IFN-g versus IL-4 expression are gated on CD4+CD8– cells and are shown for transduced (GFP+) and untransduced (GFP–) cells. Numbers
indicate the percentage of cells within each quadrant.
(B) Overlaid histograms show expression of GzmB on transduced (GFP+) and untransduced (GFP–) Zbtb7bt/t CD4+CD8– cells (plain lines). Dashed lines show
GzmB expression on untransduced CD8+ cells stimulated in parallel in the same conditions. None of these retroviral vectors affected GzmB expression in
wild-type cells (gray-shaded histograms).
(C) Wild-type CD4+ or CD8+ T cells were activated under Th2 conditions and transduced with either a Runx3-encoding retroviral vector (plain lines) or the GFP-
only control (gray filled). Overlaid histograms show GzmB expression on GFP+ and GFP– cells (dashed lines: CD8+ cells activated in the same conditions). Data
are representative of at least two separate experiments for each panel.mmunity 29, 876–887, December 19, 2008 ª2008 Elsevier Inc. 885
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Zbtb7b Function in CD4 T CellsII flow cytometer (BD Biosciences) or a modified (Cytek) FacsCalibur cytome-
ter (BD Biosciences). CD4+CD8– cells were purified from LN cells with an an-
tibody mix including anti-CD8a and magnetic beads (CD4 Negative Isolation
kit, Dynal-Invitrogen 114.15D). CD8+ bead cell purification was performed sim-
ilarly with the CD8 separation kit from Dynal. Where indicated, CD44lo cells
were sorted from bead-purified CD4+CD8– cells with Facs Vantage or Facs
Aria instruments (BD Biosciences) as described (Liu and Bosselut, 2004).
Gene and Protein Expression Analyses
Analyses of gene expression by RT-PCR were performed as described (Liu
and Bosselut, 2004) from RNA extracted with RNAqueous (Ambion) and re-
verse-transcribed with Oligo dT priming (superscript III, Invitrogen). Analyses
by qRT-PCR were performed with Taqman reagents, probes (Gata3:
Mm00484683_m1; GzmB: Mm00442834_m1; Perforin: Mm00812512_m1;
T-bet: Mm00450960_m1, Eomes: Mm01351985_m1) and an ABI PRISM
7500HT sequence detection system, all from Applied Biosystems (Jenkinson
et al., 2007). Gene-expression values are normalized to b-actin in the same
sample. Analyses of Zbtb7b protein expression were performed on cells lyzed
in 1% Triton containing buffer as previously described (Sun et al., 2005).
SUPPLEMENTAL DATA
Supplemental Data include ten figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(08)00500-1.
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